Novo Nordisk stock fell as much as 10% Monday after it said its next-generation weight loss drug didn't meet its primary target.
In this article
Novo Nordisk
stock fell over 10% Monday after it said its next-generation weight loss drug didn’t meet its primary target.
The drug, CagriSema, didn’t achieve its primary endpoint of demonstrating non-inferiority on weight loss when compared to Eli Lilly
’s rival drug tirzepatide after 84 weeks, Novo said in a statement Monday morning.
Novo Nordisk vuelve a hundirse en Bolsa al fallar los ensayos de su nuevo medicamento contra la obesidad
Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is branded ‘obsolete’
Novo Nordisk shares drop 15% after poor trial results for new obesity drug
Novo Nordisk, il farmaco anti-obesità perde la sfida con il rivale della Lilly (e crolla in borsa): «È meno efficace»
Nuovo farmaco dimagrante di Novo Nordisk batte la ritirata, Eli Lilly avanza
Novo Nordisk scivola in Borsa (-8%) dopo dati deludenti per Cagrisema - Notizie - Ansa.it
Cade Novo Nordisk a Copenaghen, il farmaco anti-obesità è meno efficace del rivale americano
